Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
CME GROUP INC.
Next earnings ≈ Jul 24, 2026 · est. from filing cadence
Last earnings +0.5% on 2026-04-22
Revenue grew 6.4% YoY; but high leverage (liabilities/equity 5.9x).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
CME GROUP INC. shows $6.52B in FY2025 revenue (+6.4% YoY), a 62.5% net margin, and 14.2% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro$19/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001156375, latest 10-Q filed 2026-04-24) · EODHD · rules-based read · as of 6/17/2026, 2:12:35 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $4.69B | $5.02B | $5.58B | $6.13B | $6.52B |
| Gross profit | — | — | — | — | — |
| Operating income | $2.65B | $3.02B | $3.44B | $3.93B | $4.23B |
| Net income | $2.64B | $2.69B | $3.23B | $3.53B | $4.07B |
| Diluted EPS | $7.29 | $7.40 | $8.86 | $9.67 | $11.16 |
| Net margin | 56.2% | 53.6% | 57.8% | 57.5% | 62.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
74 tracked peers · median
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Last 90 days: 2 open-market buys · 3 sales
| 2026-05-18 | Piell Hilda Harris Sr MD & Chief HR Officer | Sell | 5.75K @ $304.63 | $1.75M |
| 2026-05-15 | DUFFY TERRENCE A Chairman and CEO | Sell | 26.0K @ $298.14 | $7.75M |
| 2026-05-15 | DUFFY TERRENCE A Chairman and CEO | Sell | 9.00K @ $299.58 | $2.70M |
| 2026-03-26 | SHEPARD WILLIAM R Director | Buy | 1.41K @ $297.38 | $419K |
| 2026-03-26 | SHEPARD WILLIAM R Director | Buy | 62.06 @ $297.38 | $18.5K |
| 2026-03-17 | Marcus Jonathan L Sr MD General Counsel | Sell | 3.29K @ $333.37 | $1.10M |
| 2026-03-15 | McCourt Timothy Francis Sr MD Global Head Equity & FX | Award | 5.50K @ $311.40 | $1.71M |
| 2026-03-15 | McCourt Timothy Francis Sr MD Global Head Equity & FX | Tax | 2.81K @ $311.40 | $875K |
| 2026-03-15 | McCourt Timothy Francis Sr MD Global Head Equity & FX | Tax | 94.00 @ $311.40 | $29.3K |
| 2026-03-15 | Marcus Jonathan L Sr MD General Counsel | Award | 5.27K @ $311.40 | $1.64M |
| 2026-03-15 | Marcus Jonathan L Sr MD General Counsel | Tax | 2.38K @ $311.40 | $740K |
| 2026-03-15 | Marcus Jonathan L Sr MD General Counsel | Tax | 261.00 @ $311.40 | $81.3K |